ORPH.L Regulatory News (ORPH)

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

AGM Statement

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology, academic and medical device clients, will hold its Annual General Meeting today at Finsgate, 5-7 Cranwood Street, London EC1 V9EE at 11am.

Following the formal proceedings of the meeting the Chief Executive Officer, Tony Richardson, will provide the following statement:

I am delighted to report that the success that we achieved last year has continued into 2015 with further solid trading in the first half of the year. Our increasing capacity to win larger contracts was reinforced by the €4.1m contract wins announced in March from a US based Biotechnology company, as well as the more recent contract with a leading European Biotechnology company worth €2m. Our new business success rate to date has been encouraging and we have a good pipeline of potential contracts that we are working hard to convert. Following the March Placing, which raised £2m, the business is well funded to make the investment needed in business development, support systems and in key clinical operations staff to service the larger contract tenders that we are now approaching.

Progress with Labskin continues following our first sales and we are confident of seeing commercial success this year with these products. We also continue to look at a number of acquisition opportunities and look forward to providing further information as these progress.

I am delighted to welcome Jonathan Hartshorn, who started with us earlier this month as Chief Financial Officer, and I look forward to introducing him to shareholders a little later.

Finally, I would like to thank shareholders for their continued support and we look forward to a successful 2015, and beyond, for Venn.

Enquiries:

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.